This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Saarinen-Pihkala, U. M. Articles by Mellander, L. Search for Related Content PubMed PubMed Citation Articles by Saarinen-Pihkala, U. M. Articles by Mellander, L. Social Bookmarking                            What's this?

No Disadvantage in Outcome of Using Matched Unrelated Donors as Compared With Matched Sibling Donors for Bone Marrow Transplantation in Children With Acute Lymphoblastic Leukemia in Second Remission

From the Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland; Astrid Lindgrens Children’s Hospital, Karolinska Institute, Stockholm; Huddinge Hospital, Huddinge; University Children’s Hospital, Uppsala; Queen Silvia Children’s Hospital, University of Göteborg, Göteborg; and University Children’s Hospital, Lund, Sweden; Juliane Marie Center, Rigshospitalet, Copenhagen; and Aarhus University Hospital, Skejby, Aarhus, Denmark; and Rikshospitalet, Oslo, Norway.

Address reprint requests to Ulla M. Saarinen-Pihkala, MD, Division of Hematology-Oncology and Stem Cell Transplantation, Hospital for Children and Adolescents, University of Helsinki, Stenbäckinkatu 11, 00290 Helsinki, Finland; email: ulla.pihkala{at}hus.fi

PURPOSE: We evaluated the outcome of children with acute lymphoblastic leukemia (ALL) in second remission (2CR), comparing bone marrow transplantation (BMT) using either matched sibling donors or unrelated donors (URDs).

PATIENTS AND METHODS: A total of 65 patients, aged 2 months to 20 years at BMT, with ALL in 2CR underwent allogeneic BMT at seven Nordic centers during 1990 to 1997. Of the first relapses, 85% were in bone marrow; 46% occurred on therapy, and 54%, off therapy. The preparative regimens were cyclophosphamide plus total-body irradiation ± antithymocyte/antilymphocyte globulin, busulfan plus cyclophosphamide ± antithymocyte/antilymphocyte globulin, or cytarabine plus total-body irradiation. Of the allografts, 37 were from HLA-matched siblings and 28 were from URDs.

RESULTS: In the sibling versus URD graft recipient groups, the posttransplantation 5-year event-free survival was 39% versus 54% (P = .4), the estimated posttransplantation relapse rate was 76% versus 40% (P = not significant [NS]), and the toxic death rate was 19% versus 11% (P = NS). The incidence of significant (grade 2 to 4) acute graft-versus-host disease (GVHD) was 38% versus 64% (P < .05) and was 14% versus 32% (P < .10) for severe (grade 3 to 4) acute GVHD; the incidence of chronic GVHD was 26% versus 57% (P < .05) and was 13% versus 22% (P = NS) for extensive chronic GVHD in the sibling and URD groups.

CONCLUSION: BMT with matched URD allografts offers at least equal survival for children with ALL in 2CR, as compared with allografts from matched sibling donors. URD allografts were not associated with a higher toxic mortality rate, although both acute and chronic GVHD were more frequent with URD. Indications for using matched URD allografts in ALL 2CR can be considered the same as for using matched sibling donors.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				O. Ringden, S. Z. Pavletic, C. Anasetti, A. J. Barrett, T. Wang, D. Wang, J. H. Antin, P. Di Bartolomeo, B. J. Bolwell, C. Bredeson, et al. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation Blood, March 26, 2009; 113(13): 3110 - 3118. [Abstract] [Full Text] [PDF]

				A. Balduzzi, P. De Lorenzo, A. Schrauder, V. Conter, C. Uderzo, C. Peters, T. Klingebiel, J. Stary, M. S. Felice, E. Magyarosy, et al. Eligibility for allogeneic transplantation in very high risk childhood acute lymphoblastic leukemia: the impact of the waiting time Haematologica, June 1, 2008; 93(6): 925 - 929. [Abstract] [Full Text] [PDF]

				A. P. Iori, W. Arcese, F. Milano, E. Calabrese, G. F. Torelli, W. Barberi, M. G. Mascolo, L. De Felice, M. Screnci, B. Lucarelli, et al. Unrelated cord blood transplant in children with high-risk acute lymphoblastic leukemia: a long-term follow-up Haematologica, August 1, 2007; 92(8): 1051 - 1058. [Abstract] [Full Text] [PDF]

				U. M. Saarinen-Pihkala, C. Heilmann, J. Winiarski, A. Glomstein, J. Abrahamsson, J. Arvidson, A. N. Bekassy, E. Forestier, G. Jonmundsson, H. Schroeder, et al. Pathways Through Relapses and Deaths of Children With Acute Lymphoblastic Leukemia: Role of Allogeneic Stem-Cell Transplantation in Nordic Data J. Clin. Oncol., December 20, 2006; 24(36): 5750 - 5762. [Abstract] [Full Text] [PDF]

				M. Eapen, E. Raetz, M.-J. Zhang, C. Muehlenbein, M. Devidas, T. Abshire, A. Billett, A. Homans, B. Camitta, W. L. Carroll, et al. Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research Blood, June 15, 2006; 107(12): 4961 - 4967. [Abstract] [Full Text] [PDF]

				F. Locatelli, P. Nollke, M. Zecca, E. Korthof, E. Lanino, C. Peters, A. Pession, H. Kabisch, C. Uderzo, C. S. Bonfim, et al. Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS/EBMT trial Blood, January 1, 2005; 105(1): 410 - 419. [Abstract] [Full Text] [PDF]

				A. Borgmann, A. von Stackelberg, R. Hartmann, W. Ebell, T. Klingebiel, C. Peters, and G. Henze Unrelated donor stem cell transplantation compared with chemotherapy for children with acute lymphoblastic leukemia in a second remission: a matched-pair analysis Blood, May 15, 2003; 101(10): 3835 - 3839. [Abstract] [Full Text] [PDF]

				D. Hoelzer, N. Gokbuget, O. Ottmann, C.-H. Pui, M. V. Relling, F. R. Appelbaum, J. J.M. van Dongen, and T. Szczepanski Acute Lymphoblastic Leukemia Hematology, January 1, 2002; 2002(1): 162 - 192. [Abstract] [Full Text] [PDF]